Retatrutide 10mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Retatrutide is a first-in-class triple agonist — it engages the GLP-1, GIP, and glucagon receptors at the same time[1] — and has been studied for substantial weight loss and broad metabolic improvement in obesity and type 2 diabetes[2][3]. A long half-life of roughly 6 days makes a single weekly subcutaneous injection practical, while gradual titration keeps tolerability high from the first dose[1][4].

Add 2.0 mL bacteriostatic water → 5 mg/mL concentration for precise weekly dosing.
2–12 mg once weekly (gradual escalation over 12+ weeks).
At 5 mg/mL, 1 unit = 0.01 mL = 0.05 mg on a U-100 insulin syringe.
Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Important: Read the Prep & Injection Guide first — it covers the preparation and safety basics that every protocol on this site assumes.

Dosing & Reconstitution Guide

Reconstitution and accurate weekly dosing, step by step

Standard / Gradual Titration Approach (2 mL = 5 mg/mL)

Week(s)	Weekly Dose (mg)	Total weekly volume (U-100 units / mL)
Weeks 1–4	2 mg	40 units (0.40 mL)
Weeks 5–8	4 mg	80 units (0.80 mL)
Weeks 9–12	8 mg	160 units (1.60 mL)
Weeks 13+	12 mg	240 units (2.40 mL) — use 2 vials

Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration.
Typical weekly range: 2–12 mg once weekly (gradual escalation over 12+ weeks).
Easy measuring: At 5 mg/mL, 1 mg = 0.20 mL = 20 units on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Frequency: one subcutaneous injection each week. The schedule mirrors the clinical-trial protocols that drove significant weight loss — up to 24% at 48 weeks on 12 mg weekly[2] — while holding gastrointestinal effects down through gradual escalation[1][4]. Opening at 2 mg weekly rather than 4 mg markedly softens early GI effects, and any higher weekly dose simply calls for more than one vial or a split across two sites.

Reconstitution Steps

Pull 2.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly against the vial’s inner wall to avoid foaming.
Swirl or roll gently until fully dissolved — don’t shake hard.
Note the mixing date and store at 2–8 °C (35.6–46.4 °F), shielded from light.
Any dose above 1.0 mL (100 units) is best split across two injection sites. Because this 10 mg vial is reconstituted in 2.0 mL, only the 12 mg maintenance dose draws from a second vial, while doses up to 8 mg fit within a single vial.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume a 12–48 week course of weekly injections, titrated gradually up to the maintenance dose.

Requirements increase with dose escalation.
12 weeks (2 → 4 → 8 mg titration): ~6 vials
24 weeks (up to 12 mg weekly): ~20 vials
48 weeks (maintenance at 12 mg): ~49 vials
Per week: 1 syringe (once-weekly dosing)
12 weeks: 12 syringes
24 weeks: 24 syringes
48 weeks: 48 syringes
Use 2.0 mL per vial for reconstitution.
12 weeks (6 vials): 12 mL → 2 × 10 mL bottles
24 weeks (20 vials): 40 mL → 4 × 10 mL bottles
48 weeks (49 vials): 98 mL → 10 × 10 mL bottles
One for the vial stopper + one for the injection site each week.
Per week: 2 swabs
12 weeks: 24 swabs → 1 × 100-count box
24 weeks: 48 swabs → 1 × 100-count box
48 weeks: 96 swabs → 1 × 100-count box

Protocol Overview

The once-weekly regimen at a glance, drawn from the clinical-trial protocols.

▪Goal: Drive meaningful weight loss (up to ~24% of body weight) and stronger metabolic markers through triple-receptor agonism[2][5].
▪Schedule: One subcutaneous injection a week for 12+ weeks, with the dose raised gradually.
▪Dose Range: 2–12 mg weekly; trials assessed 12 mg as the highest maintenance dose[1][3].
▪Reconstitution: 2.0 mL bacteriostatic water per 10 mg vial produces 5 mg/mL — handy for precise 2–12 mg steps.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Dosing Protocol

The week-by-week titration, mapped to the clinical-trial dosing.

▪Start: 2 mg weekly for the first 4 weeks to settle tolerability[1][4].
▪Escalation: Move to 4 mg weekly for Weeks 5–8, then 8 mg weekly for Weeks 9–12[1].
▪Maintenance: 12 mg weekly from Week 13 for maximum effect; 8 mg weekly is a commonly used alternative[2].
▪Frequency: Once a week, subcutaneous — holding the same day and time each week aids consistency.
▪Cycle Length: At least 12 weeks to finish escalation; trials extended to 48 weeks with continued, progressive weight loss[2].
▪Timing: Any steady weekly schedule works; change the injection site with each dose.

Storage Instructions

Correct storage is what preserves the peptide’s stability and potency.

▪Lyophilized: Hold at −20 °C (−4 °F) or colder for long-term keeping; shield from moisture and light[11][12].
▪Reconstituted: Chill at 2–8 °C (35.6–46.4 °F) as soon as it’s mixed and use within 2–4 weeks to keep stability and potency[11].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form; keep the mixed solution clear of heat and direct sun.
▪Aliquoting: To store beyond 4 weeks, divide the unused portion into aliquots and freeze; steer clear of repeated freeze–thaw cycles, which cause degradation[12].

Important Notes

Practical points that keep weekly administration safe and consistent.

▪Weekly consistency: Lock in one day and time for the weekly injection and keep to it for the whole protocol.
▪Gradual titration is essential: Opening at 2 mg weekly instead of a higher dose markedly lowers the odds of early gastrointestinal effects[4].
▪Syringe use: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward[14].
▪Injection site rotation: Move sites week to week (abdomen, thighs, upper arms), keeping each shot at least 1 inch from the last to limit irritation and prevent lipohypertrophy[15].
▪Large volumes: When a dose needs more than 1.0 mL (>100 units), divide it across sites or draw from more than one reconstituted vial.
▪Side-effect monitoring: Mild nausea or stomach upset is normal while escalating; if it becomes notable, hold the current dose longer before stepping up.

How This Works

Retatrutide is a first-in-class triple agonist: it activates three of the body’s key metabolic hormone receptors at once — GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor[1][5]. Hitting all three together is what produces synergistic effects on appetite, metabolic rate, and glucose control that single- and dual-agonists can’t match.

Each receptor pulls a different lever: GLP-1 curbs appetite and slows gastric emptying, GIP sharpens insulin secretion and may support lipid metabolism, and glucagon-receptor activation raises energy expenditure and drives fat oxidation[5][8]. Together, they add up to a profound metabolic effect.
With an extended half-life of ~6 days, a single weekly dose holds therapeutic levels steady between injections[1].
In trials, participants on 12 mg weekly lost an average of 24% of body weight over 48 weeks[2]. In adults with type 2 diabetes, doses up to 12 mg weekly produced roughly 17% weight loss at 36 weeks alongside ~2.0% HbA1c reductions versus placebo[3].
A 2025 meta-analysis pooling three trials (878 participants) confirmed the pattern: significantly greater weight loss than placebo — about ~14% of total body weight on average — with no significant rise in overall adverse events[6][7].

Lifestyle Factors

Habits that work alongside the protocol to protect results and ease the transition.

▪Nutrition: Eat a balanced, protein-forward diet (1.0–1.2 g/kg body weight) to hold on to lean mass while losing weight[10].
▪Hydration: Keep fluids up, particularly while titrating, when GI effects peak.
▪Physical activity: Pair resistance training (2–3×/week) with moderate cardio to aid metabolic adaptation and protect muscle.
▪Sleep & stress: Aim for 7–9 hours of solid sleep and manage stress to support hormonal balance and stay on track.
▪Meal timing: Smaller, more frequent meals help some people handle GI effects during early titration.

Potential Benefits & Side Effects

What human phase 2 and phase 3 trials have reported.

▪Substantial weight loss: Up to 24% body-weight reduction by 48 weeks on 12 mg weekly[2].
▪Glycemic improvement: Marked HbA1c drops (about 2.0%) in adults with type 2 diabetes[3].
▪Metabolic benefits: Gains in lipid profile, blood pressure, and cardiovascular risk markers[1][5].
▪Convenient dosing: A single weekly subcutaneous dose is easier to stick with than daily regimens[1].
▪Gastrointestinal effects: Nausea, diarrhea, vomiting, and constipation top the list of adverse events; usually mild-to-moderate and easing with time[2][4].
▪Beginning at 2 mg weekly rather than 4 mg sharply cuts early GI events[4].
▪Injection site reactions: Mild redness, swelling, or soreness can show up at the site; rotating sites keeps it minimal.
▪Overall safety profile: Pooled trial data showed no meaningful rise in overall adverse events versus placebo[6][7].

Injection Technique

Subcutaneous injection technique, following established clinical practice and CDC guidance[13][14].

▪Wash your hands well with soap and water[14].
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Pick a site (abdomen, thigh, or upper arm) and wipe it with a fresh alcohol swab, letting it dry fully[13].
▪Carefully draw the intended dose, then check for air bubbles and push any out.
▪Pinch about a 1-inch fold of skin between thumb and forefinger[15].
▪Insert the needle into the pinch at a 90-degree angle (45 degrees if the fat layer is thin)[13][14].
▪Skip aspiration for subcutaneous shots — it isn’t needed and can add discomfort[13].
▪Press the plunger slowly and steadily until it’s fully down.
▪Pull the needle straight out and, if needed, press lightly with clean gauze.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle[14].
▪Put the reconstituted vial back in the fridge right away.
▪Shift the site each week (at least 1 inch over) to prevent lipohypertrophy[15].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity Retatrutide (10 mg vials), we point researchers to Prime Lab Peptides.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for Retatrutide 10mg.

Retatrutide (10mg Vial) Dosage Protocol Open source
1 New England Journal of Medicine (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2 trial; 48-week results) View Source ↗ Open source
2 JAMA Network (2023) Retatrutide Phase 2 Obesity Trial: detailed efficacy and safety data (24% weight loss at 12 mg weekly) View Source ↗ Open source
3 The Lancet (2023) Retatrutide in type 2 diabetes: Phase 2 trial (weight loss and glycemic outcomes at 36 weeks) View Source ↗ Open source
4 PubMed / NEJM (2023) Retatrutide dosing and tolerability: starting at 2 mg vs 4 mg reduces GI adverse events View Source ↗ Open source
5 Metabolites (PMC, 2025) Retatrutide—A Game Changer in Obesity Pharmacotherapy (comprehensive review of mechanism and trials) View Source ↗ Open source
6 Baylor University Medical Center Proceedings (PMC, 2025) Efficacy and safety of retatrutide for obesity: meta-analysis of RCTs (878 participants) View Source ↗ Open source
7 PubMed (2025) Meta-analysis: Retatrutide achieves ~14% greater weight reduction vs placebo with no increase in adverse events View Source ↗ Open source
8 Molecular Metabolism (2025) Preclinical tri-agonist NN1706 (related compound): mechanism and pharmacokinetics View Source ↗ Open source
9 Nature Reviews Endocrinology (2024) Triple agonist therapies for obesity and diabetes: clinical landscape review View Source ↗ Open source
10 Journal of Cachexia, Sarcopenia and Muscle (PMC) Protein requirements during weight loss: preserving lean mass View Source ↗ Open source
11 GenScript Peptide Storage and Handling Guidelines (technical bulletin for lyophilized and reconstituted peptides) View Source ↗ Open source
12 Bachem Handling and Storage Guidelines for Peptides (technical article on stability and freeze-thaw cycles) View Source ↗ Open source
13 Centers for Disease Control and Prevention (CDC) Vaccine Administration: Subcutaneous Injection (technique, angle, and site guidance) View Source ↗ Open source
14 NCBI Bookshelf Injection Administration Best Practices (aseptic technique, sharps disposal, and safety) View Source ↗ Open source
15 Pharmacologic Considerations of the Subcutaneous Route (PMC) Subcutaneous injection technique and site rotation to prevent lipohypertrophy View Source ↗ Open source
16 Prime Lab Peptides Retatrutide (6 mg) product page (quality documentation and specifications) View Source ↗ Open source

Contents